A New Tachyarrhythmia in a 60-Year-Old Woman

Bennett, Ari J.; Joglar, José A.

doi:10.1161/circulationaha.119.042642

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased PVCs can be a marker of digoxin side effect and potentially evolving arrhythmia. 17 If digoxin toxicity is recognized, Digifab should be given. Indications to give Digifab include any life-threatening ventricular arrhythmia, hemodynamically unstable bradyarrhythmia, and ingestion of more than 10 milligrams of digoxin in healthy adults.…”

Section: Reported Causes Of Bivtmentioning

confidence: 99%

Bidirectional Ventricular Tachycardia: Challenges and Solutions

Almarzuqi¹,

Kimber²,

Quadros³

et al. 2022

VHRM

View full text Add to dashboard Cite

Bidirectional ventricular tachycardia (BiVT) is a rare form of ventricular tachycardia that manifests on surface electrocardiogram by dual QRS morphologies alternating on a beat-to-beat basis. It was first reported in the 1920s as a complication of digoxin, and since then, it has been reported in other conditions including fulminant myocarditis, sarcoidosis, catecholaminergic polymorphic ventricular tachycardia, and Andersen-Tawil syndrome. The mechanism for BiVT is not as well known as other forms of ventricular tachycardia but appears to include typical mechanisms including triggered activity from afterdepolarizations, abnormal automaticity, or reentry. This review will go beyond the definition, surface electrocardiogram, mechanisms, causes, and treatment of BiVT as per our current understanding.

show abstract

Section: Reported Causes Of Bivtmentioning

confidence: 99%

Bidirectional Ventricular Tachycardia: Challenges and Solutions

Almarzuqi¹,

Kimber²,

Quadros³

et al. 2022

VHRM

View full text Add to dashboard Cite

show abstract

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Nicholls

Schwartz

Buhr

et al. 2021

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Preclinical data suggest that apabetalone exerts favorable effects on pathways related to myocardial structure and function and therefore could impact subsequent heart failure events. The effect of apabetalone on heart failure events after an ACS is not currently known. Methods The phase 3 BETonMACE trial was a double-blind, randomized comparison of apabetalone versus placebo on the incidence of major adverse cardiovascular events (MACE) in 2425 patients with a recent ACS and diabetes. This prespecified secondary analysis investigated the impact of apabetalone on hospitalization for congestive heart failure, not previously studied. Results Patients (age 62 years, 74.4% males, 90% high-intensity statin use, LDL-C 70.3 mg/dL, HDL-C 33.3 mg/dL and HbA1c 7.3%) were followed for an average 26 months. Apabetalone treated patients experienced the nominal finding of a lower rate of first hospitalization for heart failure (2.4% vs. 4.0%, HR 0.59 [95%CI 0.38–0.94], P = 0.03), total number of hospitalizations for heart failure (35 vs. 70, HR 0.47 [95%CI 0.27–0.83], P = 0.01) and the combination of cardiovascular death or hospitalization for heart failure (5.7% vs. 7.8%, HR 0.72 [95%CI 0.53–0.98], P = 0.04). Conclusion Apabetalone treatment was associated with fewer hospitalizations for heart failure in patients with type 2 diabetes and recent ACS. Future studies are warranted to define the potential for BET inhibition with apabetalone to prevent heart failure in patients with diabetes and ACS.

show abstract

A New Tachyarrhythmia in a 60-Year-Old Woman

Cited by 2 publications

References 3 publications

Bidirectional Ventricular Tachycardia: Challenges and Solutions

Bidirectional Ventricular Tachycardia: Challenges and Solutions

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Contact Info

Product

Resources

About